SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Sam Citron who wrote (14421)12/2/2004 10:32:49 AM
From: rkrw  Respond to of 52153
 
ENZN is diversified, INEX isn't. Approval wasn't particularly material or priced into enzn, for some reason approval was priced into inex.



To: Sam Citron who wrote (14421)12/2/2004 10:38:24 AM
From: Biomaven  Read Replies (3) | Respond to of 52153
 
ENZN vs. INEX:

Well one obvious difference is that ENZN has a number of programs whereas Inex is completely dependent on this drug. Also Enzn weakened substantially when the ODAC briefing material first came out whereas I think Inex may have been halted. So the news was already in the ENZN price, but not in the Inex price.

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News